JAGUAR HEALTH, INC. Increase (Decrease) in Contract with Customer, Liability
JAGUAR HEALTH, INC. (JAGX) reported Increase (Decrease) in Contract with Customer, Liability of -$84.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-19
- JAGUAR HEALTH, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$42.00K.
- JAGUAR HEALTH, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$42.00K.
- JAGUAR HEALTH, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$43.00K.
- JAGUAR HEALTH, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$43.00K.
- JAGUAR HEALTH, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$171.00K, a 123.65% decline from fiscal 2024.
- JAGUAR HEALTH, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $723.00K.
- JAGUAR HEALTH, INC. increase (decrease) in contract with customer, liability for fiscal 2018 was -$177.39K, a 200.00% decline from fiscal 2017.
- JAGUAR HEALTH, INC. increase (decrease) in contract with customer, liability for fiscal 2017 was $177.39K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-19 | -$84.00K 10-Q · filed 2026-08-19 | -$127.00K derived: sum of 3 quarters · filed 2026-08-19 | -$170.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | -$42.00K 10-Q · filed 2026-05-20 | -$85.00K derived: sum of 2 quarters · filed 2026-05-20 | -$128.00K derived: sum of 3 quarters · filed 2026-05-20 | -$170.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$86.00K derived: sum of 2 quarters · filed 2026-04-07 | -$128.00K derived: sum of 3 quarters · filed 2026-08-19 | -$171.00K 10-K · filed 2026-04-07 |
| 2025-09-30 | -$43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$85.00K derived: sum of 2 quarters · filed 2026-08-19 | -$128.00K 10-Q · filed 2025-11-14 | -$170.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | -$42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-19 | -$85.00K 10-Q · filed 2026-08-19 | -$127.00K derived: sum of 3 quarters · filed 2026-08-19 | -$170.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$43.00K 10-Q · filed 2026-05-20 | -$85.00K derived: sum of 2 quarters · filed 2026-05-20 | -$128.00K derived: sum of 3 quarters · filed 2026-05-20 | -$170.00K derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | -$42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$85.00K derived: sum of 2 quarters · filed 2026-04-07 | -$127.00K derived: sum of 3 quarters · filed 2026-04-07 | $723.00K 10-K · filed 2026-04-07 |
| 2024-09-30 | -$43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$85.00K derived: sum of 2 quarters · filed 2025-11-14 | $765.00K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | -$42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $808.00K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $850.00K 10-Q · filed 2025-05-15 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | -$177.39K 10-K · filed 2019-04-10 | ||
| 2018-09-30 | -$177.39K 10-Q · filed 2018-11-19 | |||
| 2017-12-31 | -$637.20K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | $177.39K 10-K · filed 2019-04-10 | ||
| 2017-09-30 | $814.59K 10-Q · filed 2018-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |